SEARCH

SEARCH BY CITATION

References

  • American Academy of Ophthalmology (2000): Preferred practice patterns: primary open-angle glaucoma. San Francisco (CA): American Academy of Ophthalmology.
  • Azuara Blanco A & Burr J (2006): The rising cost of glaucoma drugs. Br J Ophthalmol 90: 130131.
  • Beckers HJM, Schouten JSAG, Webers CAB, van der Valk R & Hendrikse F (2008): Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction. Graefes Arch Clin Exp Ophthalmol 246: 14851490.
  • van Beek LM, de Keizer RJ, Polak BC, Elzenaar PR, van Haeringen NJ & Kijlstra A (2000): Incidence of ocular side effects of topical beta blockers in the Netherlands. Br J Ophthalmol 84: 856859.
  • Bernard LM, Althin R, Dhawan R, Grima DT, Lam A & Aballea S (2003): Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France. Eur J Ophthalmol 13: S30S43.
  • Camras CB, Alm A, Watson P & Stjernschantz J (1996): Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost study groups. Ophthalmology 103: 19161924.
  • Centraal Bureau voor de Statistiek (CBS) (2003): Survival probabilities. Available at http://statline.cbs.nl [Accessed September 8, 2003].
  • Chen PP (2003): Blindness in patients with treated open-angle glaucoma. Ophthalmology 110: 726733.
  • Commissie Farmaceutische hulp (CFH) van het College voor zorgverzekeringen (Health Care Insurance Board) (2004): Farmacotherapeutisch Kompas (Pharmacotherapeutic Compass). Bohn Stafleu van Loghum: Amstelveen.
  • David R, Livingston DG & Luntz MH (1977): Ocular hypertension; a long-term follow-up of treated and untreated patients. Br J Ophthalmol 61: 668674.
  • De Natale R, Draghi E & Dorigo M (2004): How prostaglandins have changed the medical approach to glaucoma and its costs: an observational study of 2228 patients treated with glaucoma medications. Acta Ophthalmol Scand 82: 393396.
  • Denis P, Lafuma A & Berdeaux G (2004): Medical predictive factors of glaucoma treatment costs. J Glaucoma 13: 283290.
  • Detsky AS, Naglie G, Krahn MD, Redelmeier DA & Naimark D (1997): Primer on medical decision analysis: part 2-Building a tree. Med Decis Making 17: 126135.
  • Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ & Stoddart GL (2005): Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press.
  • Ellwein LB & Urato CJ (2002): Use of eye care and associated charges among the Medicare population: 1991-1998. Arch Ophthalmol 120: 804811.
  • Epstein DL, Krug JH Jr, Hertzmark E, Remis LL & Edelstein DJ (1989): A long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects. Ophthalmology 96: 14601467.
  • Gold MR, Siegel JE, Russel LB & Weinstein MC (1996): Cost-effectiveness in health and medicine. New York: Oxford University Press.
  • Gordon MO, Beiser JA, Brandt JD et al. (2002): The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 120: 714720.
  • Heijl A & Bengtsson B (2000): Long-term effects of timolol therapy in ocular hypertension: a double-masked, randomised trial. Graefes Arch Clin Exp Ophthalmol 238: 877883.
  • van der Horst FG, Webers CAB & Bours SJM (2003): Transmuraal model oogzorg (Transmural Model Eyecare). Maastricht: Datawyse.
  • Hovding G & Aasved H (1986): Prognostic factors in the development of manifest open angle glaucoma. A long-term follow-up study of hypertensive and normotensive eyes. Acta Ophthalmol Scand 64: 601608.
  • Hoyng PF & van Beek LM (2000): Pharmacological therapy for glaucoma: a review. Drugs 59: 411434.
  • Iskedjian M, Walker J, Vicente C, Trope GE, Buys Y, Einarson TR & Covert D (2003): Cost of glaucoma in Canada: analyses based on visual field and physician’s assessment. J Glaucoma 12: 456462.
  • Kamal D, Garway-Heath D, Ruben S, O’Sullivan F, Bunce C, Viswanathan A, Franks W & Hitchings R (2003): Results of the betaxolol versus placebo treatment trial in ocular hypertension. Graefes Arch Clin Exp Ophthalmol 241: 196203.
  • Kass MA, Gordon MO, Hoff MR, Parkinson JM, Kolker AE, Hart WM Jr & Becker B (1989): Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A randomized, double-masked, long-term clinical trial. Arch Ophthalmol 107: 15901598.
  • Kass MA, Heuer DK, Higginbotham EJ et al. (2002): The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120: 701713.
  • Kitazawa Y, Horie T, Aoki S, Suzuki M & Nishioka K (1977): Untreated ocular hypertension. A long-term prospective study. Arch Ophthalmol 95: 11801184.
  • Knox FA, Barry M, McGowan B & O’Brien C (2006): The rising cost of glaucoma drugs in Ireland 1996–2003. Br J Ophthalmol 90: 162165.
  • Kobelt G & Jonsson L (1999): Modeling cost of treatment with new topical treatments for glaucoma. Results from France and the United Kingdom. Int J Technol Assess Health Care 15: 207219.
  • Kobelt G, Jonsson L, Gerdtham U & Krieglstein GK (1998): Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany. Graefes Arch Clin Exp Ophthalmol 236: 811821.
  • Koch H (1989): Practice patterns of the office-based ophthalmologist, national ambulatory medical care survey, 1985. Advance data: 112.
  • Kwon YH, Kim CS, Zimmerman MB, Alward WL & Hayreh SS (2001): Rate of visual field loss and long-term visual outcome in primary open-angle glaucoma. Am J Ophthalmol 132: 4756.
  • Lee PP, Walt JG, Doyle JJ et al. (2006): A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol 124: 1219.
  • Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L & Komaroff E (2003): Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 121: 4856.
  • Lindblom B, Nordmann JP, Sellem E et al. (2006): A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden. Acta Ophthalmol Scand 84: 7483.
  • Lundberg L, Wettrell K & Linner E (1987): Ocular hypertension. A prospective twenty-year follow-up study. Acta Ophthalmol Scand 65: 705708.
  • McMahon C, Shaffer R, Hoskins H Jr & Hetherington J Jr (1979): Adverse effects experienced by patients taking timolol. Am J Ophthalmol 88: 736738.
  • Meads C & Hyde C (2003): What is the cost of blindness? Br J Ophthalmol 87: 12011204.
  • Noecker RJ & Walt JG (2006): Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications. Am J Ophthalmol 141: S15S21.
  • Odberg T & Sandvik L (1999): The medium and long-term efficacy of primary argon laser trabeculoplasty in avoiding topical medication in open angle glaucoma. Acta Ophthalmol Scand 77: 176181.
  • Oostenbrink JB, Rutten-van Molken MP & Sluyter-Opdenoordt TS (2001): Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands. J Glaucoma 10: 184191.
  • Peeters A, Schouten JSAG, Webers CAB, Prins MH, Hendrikse F & Severens JL (2008): Cost-effectiveness of early detection and treatment of ocular hypertension and primary open-angle glaucoma by the ophthalmologist. Eye 22: 354362.
  • Perry C, McGavin J, Culy C & Ibbotson T (2003): Latanoprost : an update of its use in glaucoma and ocular hypertension. Drugs Aging 20: 597630.
  • Rijksinstituut voor Volksgezondheid en milieu (1997): Volksgezondheid Toekomst Verkenning 1997. De som der delen. Utrecht: Elsevier/De Tijdstroom.
  • Schappert SM (1995): Office visits for glaucoma: United States, 1991–1992. Advance data: 114.
  • Schulzer M, Drance SM & Douglas GR (1991): A comparison of treated and untreated glaucoma suspects. Ophthalmology 98: 301307.
  • Shingleton BJ, Richter CU, Bellows AR, Hutchinson BT & Glynn RJ (1987): Long-term efficacy of argon laser trabeculoplasty. Ophthalmology 94: 15131518.
  • Stewart WC & Garrison PM (1998): Beta-blocker-induced complications and the patient with glaucoma. Newer treatments to help reduce systemic adverse events. Arch Intern Med 158: 221226.
  • Tanito M, Itai N, Dong J, Ohira A & Chihara E (2003): Correlation between intraocular pressure level and optic disc changes in high-tension glaucoma suspects. Ophthalmology 110: 915921.
  • Ticho U & Nesher R (1989): Laser trabeculoplasty in glaucoma. Ten-year evaluation. Arch Ophthalmol 107: 844846.
  • Traverso CE, Walt JG, Kelly SP et al. (2005): Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br J Ophthalmol 89: 12451249.
  • Tuulonen A, Niva AK & Alanko HI (1987): A controlled five-year follow-up study of laser trabeculoplasty as primary therapy for open-angle glaucoma. Am J Ophthalmol 104: 334338.
  • Tuulonen A, Salminen H, Linna M & Perkola M (2009): The need and total cost of Finnish eyecare services: a simulation model for 2005–2040. Acta Ophthalmol 87: 820829.
  • Ustundag C & Diestelhorst M (1997): Efficacy of argon laser trabeculoplasty: 3-year preliminary results of a prospective placebo-controlled study. Graefes Arch Clin Exp Ophthalmol 235: 354358.
  • van der Valk R, Webers CAB, Schouten JSAG, Zeegers MP, Hendrikse F & Prins M (2005): Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 112: 11771185.
  • van der Valk R, Schouten JSAG, Webers CAB, Hendrikse F & Prins MH (2006): Changes in glaucoma treatment and achieved IOP after introduction of new glaucoma medication. Graefes Arch Clin Exp Ophthalmol 244: 12671272.
  • Vass C, Hirn C, Sycha T, Findl O, Bauer P & Schmetterer L (2007): Medical interventions for primary open angle glaucoma and ocular hypertension. Cochrane Database Syst Rev Art No C: D003167.
  • Walckiers D & Sartor F (1996): Results of an epidemiological study on drug-treated intraocular hypertension in Belgium. J Clin Epidemiol 49: 489493.
  • Webers CAB, van der Valk R, Schouten JSAG, Zeegers MP, Prins M & Hendrikse F (2007): Intraocular pressure-lowering effect of adding dorzolamide or latanoprost to timolol. Ophthalmology 114: 4046.
  • Zhang WY, Po AL, Dua HS & Azuara Blanco A (2001): Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br J Ophthalmol 85: 983990.